AstraZeneca's drops colorectal cancer plans for Recentin on mixed Phase III data
This article was originally published in Scrip
Executive Summary
AstraZeneca's Recentin (cediranib) met only one of two co-primary endpoints in a Phase III metastatic colorectal cancer (mCRC) trial. Based on the results of this HORIZON II trial, the company no longer plans to file Recentin for the first-line treatment of mCRC.